These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7591282)

  • 1. Somatic mutations of von Hippel-Lindau (VHL) tumor-suppressor gene in European kidney cancers.
    Bailly M; Bain C; Favrot MC; Ozturk M
    Int J Cancer; 1995 Nov; 63(5):660-4. PubMed ID: 7591282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma.
    Whaley JM; Naglich J; Gelbert L; Hsia YE; Lamiell JM; Green JS; Collins D; Neumann HP; Laidlaw J; Li FP
    Am J Hum Genet; 1994 Dec; 55(6):1092-102. PubMed ID: 7977367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genotype-phenotype correlation in von Hippel-Lindau families with renal lesions.
    Gallou C; Chauveau D; Richard S; Joly D; Giraud S; Olschwang S; Martin N; Saquet C; Chrétien Y; Méjean A; Correas JM; Benoît G; Colombeau P; Grünfeld JP; Junien C; Béroud C
    Hum Mutat; 2004 Sep; 24(3):215-24. PubMed ID: 15300849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrative analysis of dysregulated microRNAs and mRNAs in multiple recurrent synchronized renal tumors from patients with von Hippel-Lindau disease.
    Gattolliat CH; Couvé S; Meurice G; Oréar C; Droin N; Chiquet M; Ferlicot S; Verkarre V; Vasiliu V; Molinié V; Méjean A; Dessen P; Giraud S; Bressac-De-Paillerets B; Gardie B; Tean Teh B; Richard S; Gad S
    Int J Oncol; 2018 Oct; 53(4):1455-1468. PubMed ID: 30066860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatic von Hippel-Lindau disease gene mutation in clear-cell renal carcinomas associated with end-stage renal disease/acquired cystic disease of the kidney.
    Yoshida M; Yao M; Ishikawa I; Kishida T; Nagashima Y; Kondo K; Nakaigawa N; Hosaka M
    Genes Chromosomes Cancer; 2002 Dec; 35(4):359-64. PubMed ID: 12378530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of high-grade renal cell carcinomas in rats independently of somatic mutations in the Tsc2 and VHL tumor suppressor genes.
    Toyokuni S; Okada K; Kondo S; Nishioka H; Tanaka T; Nishiyama Y; Hino O; Hiai H
    Jpn J Cancer Res; 1998 Aug; 89(8):814-20. PubMed ID: 9765616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cloning of the rat homologue of the von Hippel-Lindau tumor suppressor gene and its non-somatic mutation in rat renal cell carcinomas.
    Kikuchi Y; Kobayashi E; Nishizawa M; Hamazaki S; Okada S; Hino O
    Jpn J Cancer Res; 1995 Oct; 86(10):905-9. PubMed ID: 7493907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Von Hippel-Lindau disease and sporadic renal cell carcinoma.
    Zbar B
    Cancer Surv; 1995; 25():219-32. PubMed ID: 8718521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular detection of von Hippel-Lindau gene mutations in urine and lymph node samples in patients with renal cell carcinoma: potential biomarkers for early diagnosis and postoperative metastatic status.
    Ashida S; Furihata M; Tanimura M; Sugita O; Yamashita M; Miura T; Moriyama M; Shuin T
    J Urol; 2003 Jun; 169(6):2089-93. PubMed ID: 12771725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of somatic mutations in the von Hippel-Lindau (VHL) gene in a patient with renal cell carcinoma.
    Wang WC; Chen HJ; Tseng YH; Lai YC
    J Formos Med Assoc; 2009 Nov; 108(11):886-93. PubMed ID: 19933033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should endolymphatic sac tumors be considered part of the von Hippel-Lindau complex? Pathology case report.
    Tibbs RE; Bowles AP; Raila FA; Fratkin JD; Hutchins JB
    Neurosurgery; 1997 Apr; 40(4):848-55; discussion 855. PubMed ID: 9092862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular epidemiology of VHL gene mutations in renal cell carcinoma patients: relation to dietary and other factors.
    Hemminki K; Jiang Y; Ma X; Yang K; Egevad L; Lindblad P
    Carcinogenesis; 2002 May; 23(5):809-15. PubMed ID: 12016154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel mutations of the von hippel-lindau tumor-suppressor gene and rare DNA hypermethylation in renal-cell carcinoma cell lines of the clear-cell type.
    Meyer AJ; Hernandez A; Florl AR; Enczmann J; Gerharz CD; Schulz WA; Wernet P; Ackermann R
    Int J Cancer; 2000 Sep; 87(5):650-3. PubMed ID: 10925357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma.
    Kim JH; Jung CW; Cho YH; Lee J; Lee SH; Kim HY; Park J; Park JO; Kim K; Kim WS; Park YS; Im YH; Kang WK; Park K
    Oncol Rep; 2005 May; 13(5):859-64. PubMed ID: 15809750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence, morphology and biology of renal cell carcinoma in von Hippel-Lindau disease compared to sporadic renal cell carcinoma.
    Neumann HP; Bender BU; Berger DP; Laubenberger J; Schultze-Seemann W; Wetterauer U; Ferstl FJ; Herbst EW; Schwarzkopf G; Hes FJ; Lips CJ; Lamiell JM; Masek O; Riegler P; Mueller B; Glavac D; Brauch H
    J Urol; 1998 Oct; 160(4):1248-54. PubMed ID: 9751329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of the von Hippel-Lindau disease tumor suppressor gene.
    Latif F; Tory K; Gnarra J; Yao M; Duh FM; Orcutt ML; Stackhouse T; Kuzmin I; Modi W; Geil L
    Science; 1993 May; 260(5112):1317-20. PubMed ID: 8493574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Von Hippel-Lindau gene alterations in sporadic benign and malignant pheochromocytomas.
    Dannenberg H; De Krijger RR; van der Harst E; Abbou M; IJzendoorn Y; Komminoth P; Dinjens WN
    Int J Cancer; 2003 Jun; 105(2):190-5. PubMed ID: 12673678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Von Hippel-Lindau disease: recent genetic progress and patient management. Francophone Study Group of von Hippel-Lindau Disease (GEFVH)].
    Richard S; Giraud S; Beroud C; Caron J; Penfornis F; Baudin E; Niccoli-Sire P; Murat A; Schlumberger M; Plouin PF; Conte-Devolx B
    Ann Endocrinol (Paris); 1998; 59(6):452-8. PubMed ID: 10189987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.